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Abstract: The current prevalence of infections caused bymultidrug-resistant (MDR) organisms
is a global threat, and thus, the development of new antimicrobial agents with activity against
these pathogens is a healthcare priority. Ceftolozane–tazobactam (C/T) is a new combination of
a cephalosporin with a β-lactamase inhibitor that shows excellent in vitro activity against a broad
spectrum of Enterobacteriaceae and Pseudomonas aeruginosa, including extended spectrum β-
lactamase-producing (ESBL) strains and MDR or extensively drug-resistant (XDR)
P. aeruginosa. In phase III randomized clinical trials, C/T demonstrated similar efficacy to
meropenem for the treatment of complicated intra-abdominal infections (cIAIs) and superior
efficacy to levofloxacin for the treatment of complicated urinary tract infections (cUTIs),
including pyelonephritis. The drug is generally safe and well tolerated and its PK/PD profile is
very favorable. Observational studies with C/T have revealed good efficacy for the treatment of
different types of infection caused by MDR or XDR P. aeruginosa, including some that
originated from the digestive or urinary tracts. The place of C/T in therapy is not well defined,
but its use could be recommended in a carbapenem-sparing approach for the treatment of
infections caused by ESBL-producing strains or for the treatment of infections caused by
P. aeruginosa if there are no other more favorable therapeutic options. Further clinical experience
is needed to position this new antimicrobial drug for the empirical treatment of cIAIs or cUTIs.
Keywords: ceftolozane-tazobactam, complicated intra-abdominal infections, complicated
urinary tract infections, multidrug-resistant Pseudomonas aeruginosa
Extent of complicated intra-abdominal and urinary
tract infections in the era of bacterial multiresistance
Complicated intra-abdominal infections (cIAIs) are defined as infections resulting
from perforation of the gastrointestinal tract that extend into the peritoneal space
and are associated with either abscess formation or peritonitis.1 This type of
infection is usually polymicrobial and dominated by Gram-negative bacilli, parti-
cularly Enterobacteriaceae and Pseudomonas aeruginosa (found less frequently),
and Gram-positive cocci and anaerobes have also been identified.2
These infections require immediate surgery combined with adequate antimicro-
bial treatment. The most widely used antimicrobial treatments are the combination
of cefotaxime or ceftriaxone with metronidazole and monotherapy with amoxicillin/
clavulanic acid. However, the use of piperacillin/tazobactam and even carbapenems
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is becoming more common, even for community-acquired
infections. The reason for this change is the unstoppable
dissemination of extended spectrum β-lactamase-
producing (ESBL) enterobacteria. The global prevalence
of class A ESBL-producing enterobacteria fecal coloniza-
tion is 14%, as inferred from a meta-analysis that included
a population of 28,909 healthy people from five conti-
nents, and this prevalence shows an annual increase of
5.4%. Africa and Asia are the continents with the highest
prevalence, with rates of 45% and 15%, respectively, and
these are followed by Southern Europe (6%), Central
Europe (3%), Northern Europe (4%) and Northern
America (2%).2 In this context, the available antimicrobial
treatment for cIAIs can be suboptimal, particularly in the
countries and hospitals with the most unfavorable
epidemiology.
The definition of complicated urinary tract infections
(cUTIs) varies among studies, but the guidelines3,4 define
cUTIs as urinary tract infections in patients with one or
more of the following conditions: a) men, children, preg-
nant women or individuals aged ≥65 years; b) women with
functional or anatomical urinary tract abnormalities that
cause obstruction or voiding disorders, any sort of ureteral
derivation or foreign body (including indwelling bladder
catheters), polycystic kidney disease, single kidney, recent
(within 1 month) instrumentation or urinary tract surgery,
diabetes mellitus, renal insufficiency or transplantation,
other immunosuppressed states or underlying diseases
(liver cirrhosis, active malignancy, congestive heart fail-
ure); and c) severe sepsis. The above conditions are fre-
quently used to determine whether the patient needs to be
admitted to the hospital, and some of these cUTIs are more
likely to be related to multidrug-resistant (MDR) patho-
gens. However, the resistance rates in some of these popu-
lations, such as men, the elderly, patients with diabetes or
acute urinary tract infection (UTI) following ureteral stone
obstruction, might be similar to those of uncompli-
cated UTI.
The increased risk of UTIs due to MDR microor-
ganisms is substantial in the group of healthcare-
associated urinary tract infections (HCA-UTIs), which
includes the following: a) patients who received intra-
venous therapy, wound care or specialized nursing care
at home in the 30 days prior to the episode; b) patients
who attended a hemodialysis center or received intra-
venous chemotherapy in the 30 days before the episode;
c) patients who were hospitalized in an acute-care hos-
pital for ≥2 days in the 90 days before the current
hospitalization; d) patients who reside in a nursing
home or long-term care facility (LTCF); and e) patients
who underwent an invasive urinary procedure in the 30
days before the episode or who have a long-term
indwelling urethral catheter. This increased resistance
has impacted the choice of empiric antibiotic therapy
because higher failure rates with a poor outcome could
be obtained if an adequate antibiotic therapy is not
administered.3,4
Two recent studies5,6 found that the P. aeruginosa
etiology and resistance rates in HCA-UTIs were higher
than those in community-acquired urinary tract infections
(CA-UTIs). In our experience the resistance rates of CA-
UTIs and HCA-UTIs among 607 patients with acute pye-
lonephritis (APN) were as follows: amoxicillin/clavulanic
acid, 22.4% versus 53.2%; cefuroxime, 7.7% versus
43.5%; cefotaxime, 4.3% versus 32.6%; ciprofloxacin,
22.8% versus 74.5%; and cotrimoxazole, 34.5% versus
58.7%. In both studies, previous antibiotic use (in the
last 3 months) was also identified as an independent risk
factor for antibiotic resistance.
Currentmanagement of complicated
intra-abdominal and urinary tract
infections
Complicated intra-abdominal infections
The management of cIAIs includes a combination of
source control and adjunctive antibiotic therapy. Source
control is defined as any procedure that eliminates infec-
tious foci, control factors that promote ongoing infection,
and correct or control anatomic derangements that restore
normal physiologic function7 and can be achieved surgi-
cally and/or by percutaneous drainage of the associated
abscess.
As mentioned above, due to the increasing resistance to
aminopenicillins, third-generation cephalosporins, fluoro-
quinolones and aminoglycosides among Escherichia coli
and the spread of ESBL-producing Enterobacteriaceae,
antibiotic recommendations, in particularly those for high-
risk and healthcare-associated infections,8,9 have changed
because studies have shown that ineffective antimicrobial
therapy is strongly associated with unfavorable outcomes
in septic patients.10
For patients with mild-to-moderate community-acquired
cIAIs, the current recommendation is to use narrower-spec-
trum antibiotics with activity against Enterobacteriaceae,
aerobic streptococci, and anaerobes, and avoid
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antipseudomonal coverage. Cefotaxime or ceftriaxone plus
metronidazole or ertapenem are some recommended agents
for the initial therapy. As mentioned above, amoxicillin/
clavulanic acid and fluoroquinolones are no longer advisable
as an empiric treatment due to frequent resistance, and clin-
damycin should also be avoided due to the increasing resis-
tance rates among Bacteroides fragilis.1,11,12
Empirical treatment with broad-spectrum agents is
needed for patients with high-risk community-acquired
cIAIs. At present, piperacillin–tazobactam, doripenem,
imipenem–cilastatin, meropenem, ceftazidime or cefe-
pime plus metronidazole are some of the recommended
regimens.1,11,12 For the empirical treatment of health-
care-associated cIAIs, the choice of antibiotic should
be guided by regional epidemiological and resistance
data.1,11,12 ESBL-producer coverage is usually needed,
and the use of piperacillin/tazobactam in this scenario
remains controversial.13 Thus, carbapenems have been
considered the preferred agents, but the spread of car-
bapenemase-producing Enterobacteriaceae (CPE) and
MDR P. aeruginosa has become a global threat world-
wide. Therefore, new antibiotics, such as ceftolozane/
tazobactam (C/T) and ceftazidime/avibactam in combi-
nation with metronidazole appear promising.
Finally, the tailoring of antimicrobial treatment once
the results of susceptibility reports become available is
essential, and limiting the length of antimicrobial therapy
to four days in patients with adequate source control is
also important.14 Patients showing ongoing signs of infec-
tion after five days of adequate antibiotic treatment should
undergo a diagnostic investigation and be reassessed for
a possible new source control intervention.1
Complicated urinary tract infections
According to the IDSA guidelines,4 the empiric antimicro-
bial therapy for APN should be based on local suscept-
ibility antibiotic data. It has been recommended that
antibiotics with a resistance rate higher than 10% should
be avoided in empirical therapy. However, this recommen-
dation is not based on clinical studies.
The mortality rates of CA-UTIs are low (1%), and in
our clinical practice, an inadequate empirical antibiotic is
not associated with a worse outcome, particularly in
patients without septic shock.5 Thus, when discussing
a new local guideline for the treatment of cUTIs, the
severity of the underlying infection and the risk of an
MDR microorganism should be balanced with the initia-
tion of an antibiotic with broad-spectrum coverage, such
a carbapenem, because the overuse of carbapenems might
increase the risk of infections due to CPE.3–6,15,16
Risk factors for ESBL-producing bacterial infections are
previous colonization, recurrent UTIs, previous use of third-
generation cephalosporins or quinolones, healthcare-
associated infections and recent travel to high-risk areas.
In our setting, Germany and other countries with high
resistance rates to amoxicillin, cotrimoxazole, amoxicillin/
clavulanic acid, and quinolones, a second- or third-
generation cephalosporin or an aminoglycoside are ade-
quate initial options for non-severe patients without risk
factors for ESBL-producers.3,5,6 Aztreonam, an aminogly-
coside, a carbapenem, or intravenous fosfomycin could be
used for allergic patients.
For more severe infections or patients with risk factors
for ESBL-producing bacteria, a carbapenem or piperacillin–
tazobactam may be used.17 Other options could be amino-
glycosides or intravenous fosfomycin, although the experi-
ence with these antimicrobial agents is limited.
An antipseudomonal agent should be used for the treat-
ment of nosocomial or health-care cUTIs because
P. aeruginosa is the most commonly found pathogen
(15% of our HCA-UTIs). The choice of empirical agent
should be based on local susceptibility data. In our setting,
25–35% of the isolated agents are resistant to piperacillin–
tazobactam, ceftazidime, aztreonam, cefepime, fosfomy-
cin, gentamicin, tobramycin or antipseudomonal carbape-
nem. Amikacin (which has the lowest resistance rates)
should be included in the treatment of septic cases. C/T
or ceftazidime–avibactam might be other alternatives, par-
ticularly for cases with previous MDR or extremely drug-
resistant (XDR) P. aeruginosa colonization. In countries
with a high incidence and risk factors for carbapenem-
resistant microorganisms, ceftazidime–avibactam, aztreo-
nam, aminoglycosides, fosfomycin, colistin or
a combination with a carbapenem should be considered.
For patients with indwelling urinary devices and septic
shock, antimicrobial coverage against multiresistant Gram-
positive microorganisms, such as methicillin-resistant
Staphylococcus aureusand Enterococcus faecium, should
be considered; however, a recent study that included con-
secutive adult (mainly elderly) patients with a chronic
indwelling catheter-associated UTI and sepsis revealed
that appropriate antibiotic treatment had no significant
effect on short- and long-term survival or on the length
of stay and length of febrile illness. The overall mortality
was approximately 30%, but the mortality rate of patients
with an MDR Gram-negative infection and that of
Dovepress Escolà-Vergé et al
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patients with enterococcal infection were 55% and only
8.6%, respectively.18 These data suggest that enterococci
likely have little impact on mortality.
Spectrum and in vitro activity of
ceftolozane/tazobactam
Chemistry and mode of action
C/T is a new combination of a novel semisynthetic anti-
pseudomonal cephalosporin with a well-established β-
lactamase inhibitor (2:1 ratio).19 The approved indications
of C/T are the treatment of cUTIs and the treatment of
cIAIs when administered in combination with metronida-
zole, and it is currently investigated in phase III trials for
the treatment of hospital-acquired pneumonia.
Ceftolozane is an oxyimino-aminothiazolyl cephalos-
porin that is structurally similar to ceftazidime but has
a modified side chain that contributes to the stability of
the drug in the presence of AmpC β-lactamases, prevents
the hydrolysis of the β-lactam ring, and thus confers potent
activity against P. aeruginosa.20,21 This cephalosporin
exerts its bactericidal activity by binding to penicillin-
binding proteins (PBPs) and causing cell death.21
Compared with ceftazidime, ceftolozane shows at least two-
fold higher potency in terms of minimum inhibitory con-
centration (MIC) and binding affinities for PBP1b, PBP1c,
PBP2, and PBP3.21 Ceftolozane is not a substrate of the
carbapenem-specific porin OprD or the efflux pumps found
in P. aeruginosa.22 However, the ceftolozane activity can be
affected by some other β-lactamases, such as ESBLs. Thus,
it has been formulated in combination with tazobactam to
broaden its antimicrobial activity.23 Tazobactam is a sulfone
β-lactamase inhibitor that binds irreversibly to the active
site of serine β-lactamases and thereby protects the β-lactam
against hydrolysis. It inhibits most class A narrow-spectrum
β-lactamases, ESBLs, and some class C enzymes and
enhances the activity of ceftolozane against some ESBL-
producing Enterobacteriaceae and anaerobes.24,25
Spectrum and in vitro activity
C/T primarily shows in vitro activity against many aerobic
Gram-negative bacilli, including most ESBL-producing
E. coli (particularly TEM- and CTX-M-type ESBLs), but
its potency against ESBL-producing K. pneumoniae is
lower.23,26,27 Several studies have tested the in vitro activity
of C/T against clinical isolates from intra-abdominal and
urinary tract infections (Table 1).28–30 C/T, amikacin, and
meropenem are the antibiotics with the highest activity
against Enterobacteriaceae.26,30 C/T is very active against
E. coli (MIC50/90, 0.25/0.5 mg/L; 98.5–99.9% inhibited at
an MIC of ≤8 mg/L), and many of the MDR (MIC50/90, 0.5/
2–>32 mg/L) and ESBL-phenotype strains (MIC50/90, 0.5/
2–>32 mg/L). It also showed activity against most
K. pneumoniae strains (MIC50/90, 0.25/16 mg/L,
88.9–89.6% inhibited at an MIC of ≤8 mg/L), but elevated
MIC values were found for some ESBL-phenotype strains
(MIC50/90, 4–8/>32 mg/L) and MDR (MIC50/90, 16/>32 mg/
L).29 C/T was very active as well against other
Enterobacteriaceae, such as Enterobacter spp. (MIC50/90,
0.5/8 mg/L), Citrobacter spp. (MIC50/90, 0.25/32 mg/L),
Serratia spp. (MIC50/90, 0.5/2 mg/L), K. oxytoca
(MIC50/90, 0.25/2 mg/L), Proteus mirabilis (MIC50/90, 0.5/
0.5 mg/L), and indole-positive Proteae (MIC50/90, 0.25/
0.5 mg/L).29,30 However, C/T lacks activity against CPE
(MIC50/90, 32/>32 mg/L)
30,31 because it has no activity
against metallo-β-lactamases, K. pneumoniae carbapene-
mases, and class D enzymes.23
However, the standout quality of C/T is its singular
potency against P. aeruginosa. C/T generally showed four-
fold higher activity against P. aeruginosa compared with
ceftazidime,28 and it was the most potent β-lactam agent
and inhibited >90% of isolates at an MIC of <8 mg/L.28,30
In addition, C/T had activity against many MDR
P. aeruginosa strains (MIC50/90, 2–4/>32 mg/L), ceftazi-
dime-nonsusceptible strains (MIC50/90, 2–4/>32 mg/L),
and meropenem-nonsusceptible strains (MIC50/90, 2/
>32 mg/L).29 Only colistin was more active; specifically,
colistin inhibited 99.5% of isolates.31 However, C/T has
no in vitro activity against other nonfermenting bacteria
such as Acinetobacter spp. or Stenotrophomonas spp.
In contrast, C/T lacks activity against many Gram-
positive pathogens. Although it shows some in vitro activity
against Streptococcus species, it has very limited activity
against S. aureus and no anti-enterococcal activity. The
activity of C/T against anaerobic bacteria is very variable:
it shows in vitro activity against Fusobacterium spp., ade-
quate activity against B. fragilis and Prevotella, and low or
no activity against other Bacteroides spp. and Clostridium
spp.32 Based on this finding, metronidazole should be added
to C/T to ensure for anaerobic coverage in cIAIs.33–35
Pharmacokinetics and pharmacodynamics
of ceftolozane/tazobactam
When ceftolozane is administered as a 1-h intravenous infusion
at a dose of 1.5 g (1 g of ceftolozane and 0.5 g of Tazobactam),
Escolà-Vergé et al Dovepress
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including when it is administered at multiple doses, it exhibits
dose-linear pharmacokinetics (PK), with a mean Cmax of
74 mg/dL (Table 2).19,36–39 Unlike piperacillin, which
increases the tazobactam levels, the combination of ceftolo-
zane with tazobactam does not affect the PK of tazobactam.
The mean plasma half-life is approximately 2.3 h and the
protein binding is approximately 20%. The steady-state dis-
tribution volume (VD) of ceftolozane is approximately 14 L,
which is close to the average extracellular volume, which
suggests that ceftolozane can reach its therapeutic levels at
extracellular sites of infection. The VD might be increased in
patients with obesity and infection.19 The plasma to epithelial
Table 1 In vitro activity of ceftolozane–tazobactam against clinical isolates from intra-abdominal and urinary tract infections
Source Pathogen Number of
isolates
TOL/TAZ
MIC50 (µg/mL;
range)
TOL/TAZ
MIC90 (µg/mL;
range)
TOL/TAZ S%a
Aerobic Gram-negative
organisms isolated from
intra-abdominal and
urinary tract infections
in hospitals in Europe
and the USA (2012)29
Escherichia coli 1,674 0.25 0.5 98.5–99.9
MDR E. coli 85 0.5 2 to >32 75–98.6
K. pneumoniae 442 0.25 16 88.9–89.6
MDR K. pneumoniae 78 16 >32 NR
Enterobacter spp. 228 0.25–0.5 4–8 NR
Citrobacter spp. 113 0.25 2 NR
Proteus mirabilis 117 0.5 0.5 NR
P. aeruginosa 327 0.5 4 93.4–95.7
MDR P. aeruginosa 59 2–4 >32 65–73.7
XDR P. aeruginosa 43 4–8 >32 56.7–61.5
CAZ-NS P. aeruginosa 61 2–4 >32 60–80.8
MEM-NS P. aeruginosa 77 2 >32 75.5–79.2
Pathogen Number of
isolates
TOL/TAZ
MIC50 (µg/mL)
TOL/TAZ
MIC90 (µg/mL)
TOL/TAZ S%
(CLSI/EUCAST)
Enterobacteriaceae and
Pseudomonas aeruginosa
causing urinary tract and
intra-abdominal infec-
tions in Europe (2012–
2015)30
Enterobacteriaceae 5,950 0.25 1 93.5/91.3
ESBL non-CRE phenotype 906 0.5 8 82.8/74.9
Escherichia coli 3,460 0.25 0.5 98.8/98
ESBL non-CRE phenotype 559 0.5 2 92.7/87.8
K. pneumoniae 917 0.25 >32 79.3/75.8
ESBL phenotype 373 4 >32 49.1/41.6
ESBL non-CRE phenotype 280 1 >32 65.4/55.4
Enterobacter spp. 432 0.5 8 78/69.7
Enterobacter cloacae 278 0.5 16 76.6/70.1
Citrobacter koseri 101 0.25 0.5 100/100
Citrobacter freundii 111 0.25 8 79.3/78.4
P. mirabilis 368 0.5 0.5 97.3/95.7
ESBL phenotype 32 1 8 71.9/56.2
Indole-positive Proteeae 237 0.25 1 97.5/94.9
Serratia spp. 77 0.5 2 98.7/88.3
P. aeruginosa 603 0.5 4 91.7/91.7
CAZ-NS P. aeruginosa 139 4 >32 65.5/65.5
MEM-NS P. aeruginosa 126 2 >32 65.9/65.9
PIP/TAZ-NS P. aeruginosa 162 2 >32 70.4/70.4
Notes: aPercentage of isolates inhibited at an MIC of ceftolozane-tazobactam of ≤8 mg/L. Adapted with permission from Sader HS, Farrell DJ, Flamm RK, Jones RN.
Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States
hospitals (2012). J Infect. 2014;69(3):266–277. Copyright © 2014 The British Infection Association. Published by Elsevier Ltd. All rights reserved.29 And from: Pfaller MA,
Bassetti M, Duncan LR, Castanheira M. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosacausing urinary tract and
intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012–15). J Antimicrob Chemother. 2017;72(5):1386–1395. © The Author 2017.
Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.30
Abbreviations: TOL/TAZ, ceftolozane–tazobactam; MIC, minimum inhibitory concentration; S, susceptible; MDR, multidrug-resistant; XDR, extensively drug-resistant;
CAZ-NS, ceftazidime-non-susceptible; MEM-NS, meropenem-non-susceptible; ESBL, extended-spectrum β-lactamase; CRE, carbapenem-resistant Enterobacteriaceae; PIP/
TAZ-NS, piperacillin–tazobactam-non-susceptible.
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lining fluid penetration (ELF) of ceftolozane is approximately
50%, with a 42% interindividual variability.40 To our knowl-
edge, there are no data on biliary excretion.
Ceftolozane is mainly eliminated by renal excretion,
and tazobactam is mainly eliminated by renal excretion
and by an M1 metabolite (Table 2). Ceftolozane has
a linear PK over the range of renal function, and dose
adjustments are required for subjects who show creatinine
clearance (CLCr) <50 mL/min.
36,37 Because approximately
90% of the drug is removed during hemodialysis, it should
be administered after dialysis.
Similar to other cephalosporins, C/T is bactericidal,
and the pharmacodynamic (PD) parameter that best pre-
dicts the bacteriologic efficacy is the time above the MIC
(T>MIC) for 40–50% of the dosing interval.36,37 Based on
Monte Carlo simulation models the probabilities of target
attainment (PTAs) with a C/T dose of 1.5 g every 8 h for
50% T>MIC are 100% with an MIC ≤4 mg/L and 90%
with an MIC =8 mg/L. For patients with pneumonia, and
MIC values up to 8 mg/L, the PTAs in ELF for 40% and
50% T>MIC are 75% and 59%, respectively, and for
a dose of 3 g every 8 h these values increase to 96% and
88%, respectively. Thus, it has been suggested that higher
doses should be administered to patients with
pneumonia.40
For patients with cUTIs or cIAIs, the conventional dose
of 1.5 g every 8 h is used, but real-life studies for the
treatment of XDR P. aeruginosa infections have used higher
doses, particularly for patients with abscesses, due to the
lower penetration of antibiotics at the site of the infection.41
Although the VD and ClCr might be different from that
of healthy adults, a recent study of severely obese patients
(BMI >35 kg/m2) achieved a PTA of bactericidal activity
of >90% at an MIC up to 8 mg/L. Moreover, pivotal phase
3 studies on cUTIs and cIAIs revealed similar clinical
outcomes in severely obese and nonobese patients, and
thus, no drug adjustments are needed in these cases.42
The FDA-approved dose adjustments for C/T for patients
with renal failure (RF) are as follows: for a ClCr of
30–50 mL/min, 500/250 mg/8 h; for a ClCr of
15–29 mL/min, 250/125 mg/8 h, and for end-stage renal
disease (EERD), loading dose of 500/250 followed by 100/
50 mg/8 h.19 However, two randomized controlled trials
(RCT) on cIAIs and cUTIs showed that the clinical outcome
in patients with moderate RF, which was observed in
approximately 6% of cases, was lower compared with that
of patients with mild or no RF.43 Moreover, a recent study
revealed that patients with EERD and renal-replacement
therapy showed lower cure rates.44
In a recent review, that included >10,000 patients with
different types of infections, approximately 20% of the
patients with cUTIs or cIAIs had acute kidney failure
(AKF), which resolved by 48 h in >50% of the cases.45
These data suggest that in septic patients with AKF, renal
clearance improvement might lead to lower antibiotic
plasma levels which could partially explain the higher
failure rates observed in cases with RF. Thus, close renal
clearance monitoring is necessary in cases with AKF.
For patients on hemodialysis and difficult-to-treat infec-
tions, such as P. aeruginosa pneumonia, higher doses (a
loading dose of C/T of 1.5 g followed by 300 mg/8 h) have
been administered.46 There are scarce data for critically ill
patients on continuous hemofiltration. It has been suggested
that a C/T dose of 1.5 g/8 h administered during an extended-
infusion time of 4 h might work.47
C/T has a low potential for clinically relevant drug–drug
interactions because it is not a substrate for CYP and is not
transported by OAT1 and OAT3 enzymes.48
Importance of inappropriate
treatment in complicated
intra-abdominal and urinary tract
infections
Severe sepsis and septic shock remain a significant public
health concern. Although the associated mortality has
Table 2 Pharmacokinetics of ceftolozane–tazobactam in
healthy adults38,39
Antibiotic (1 g ceftolo-
zane – 0.5 g tazobactam)
Ceftolozane Tazobactam
Cmax mg/dl 58–92 18.0–18.4
Plasma half-life (h) 1.86−2.64 1.0–1.1
Protein binding (%) 16–21 30%
AUC (mg h/L) 143–230 24–25
Volume of distribution (L) 13–17 18.2
Epithelial lining fluid (ELF) (%) 0.46–0.60 44–46
ELF (mean mg/dL) 21 8
Urinary elimination (%) 97−100 >80%
Hemodialysis removal >90% -
Notes: Adapted from: Miller B, Hershberger E, Benziger D, Trinh M, Friedland I.
Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult
subjects following single and multiple ascending doses. Antimicrob Agents
Chemother. 2012;56(6):3086–3091. Copyright © 2012, American Society for
Microbiology. All Rights Reserved.38 And from: Ge Y, Whitehouse MJ, Friedland I,
Talbot GH. Pharmacokinetics and safety of CXA-101, a new antipseudomonal
cephalosporin, in healthy adult male and female subjects receiving single and multi-
ple-dose intravenous infusions. Antimicrob Agents Chemother. 2010;54(8):3427–3431.
Copyright © 2010, American Society for Microbiology.39
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decreased due to increased awareness and improved man-
agement, it remains high, and a value of approximately
20% was obtained in the most recent multicenter trials.49
In 2010, a Cochrane Review on patients with sepsis con-
cluded that although there is some evidence supporting the
early administration of antimicrobials for these patients,
a strong recommendation cannot be provided given the lack
of prospective trials.50 The Survival Sepsis Campaign (SSC)
released their latest guidelines in 2012, which included state-
ments emphasizing that in patients with septic shock (1B) or
severe sepsis (1C) antibiotics should be administered within
an hour of recognition.51 A recent systematic review of the
available literature (2005–2015) concluded that patients with
septic shock who received appropriate antimicrobial therapy
within 1 h of recognition had the greatest benefit inmortality.49
In patients with severe sepsis or septic shock, the control
of the infectious foci (for example, abscess drainage in
intrabdominal infection or insertion of a pig-tail urinary
tract catheter for ureter obstruction) also has an important
impact on mortality. In this sense, in a large study that
included 3,663 patients with severe sepsis admitted to the
ICU, lower mortality (21.2% versus 25.1%) was detected in
those who underwent source control for the infectious foci.52
In UTIs, discordant antimicrobial therapy selected based
on in vitro antimicrobial susceptibility test results does not
always yield a poor clinical outcome of the nonbacteremic
UTI, because urinary concentrations of most antimicrobial
agents are much higher than those in blood.53 However, in
community-acquired bacteremic APNs, discordant empirical
therapy leads to a notably worse early clinical response and
longer hospital stay than concordant therapy, even though it
does not affect the overall mortality or clinical cure rates.54
Other studies have found that appropriate antibiotic therapy
has no impact on mortality but reduces the hospital stay and
costs.55,56 Most likely, appropriate antibiotic therapy has no
impact on mortality because the death rates related to APN
are low (1%),5 even in elderly febrile UTI patients with
severe underlying conditions.18 However, in our experience
with APN, significantly higher (8.5% versus 14.7%, p>0.01)
relapse rates are obtained if antibiotic therapy is not tailored
based on available susceptibility data.5
An antimicrobial-based approach for the treatment of
cIAIs always involves a delicate balance between the
optimization of empirical therapy, which has been shown
to improve clinical outcomes, in some situations, and the
reduction of excessive antimicrobial use, which has been
proven to increase the rate of emergence of antimicrobial-
resistant strains. In several reviews or guidelines,1,12 it has
been suggested that antimicrobial therapy plays an impor-
tant role in the management of cIAIs. In severe septic
patients, an insufficient or otherwise inadequate antimicro-
bial regimen is one of the variables most strongly asso-
ciated with an unfavorable outcome. To our knowledge,
the impact of an adequate empirical antimicrobial therapy
on conditions with low mortality, such as noncomplicated
appendicitis and non-severe cholecystitis, has not been
adequately studied when the patients are treated with
early surgery, but in our opinion the place of antibiotic
therapy is probably irrelevant, because mortality is very
low, and the recommended postoperative duration of ther-
apy is very short. Excessive antimicrobial use might con-
tribute to the emergence and spread of drug-resistant
microorganisms and increase the overall treatment costs.12
In the IDSA guidelines1 for IAI, the selection of the
appropriate antimicrobial regimen is selected primarily
based on the presence or absence of risk factors for
potential failure. The populations of patients at high
risk include those with severe anatomically unfavorable
infections or healthcare-related infections. In the WSES
guidelines, high-risk patients are those with cIAIs with
a specific risk for antimicrobial-resistant bacteria and/
or a severe clinical IAI.57 In the worldwide CIAOW
study on cIAIs,58 which included 1,898 patients with
an overall mortality of 10%, the factors associated with
a higher mortality were the presence of sepsis or septic
shock, a health-care infection, colonic nondiverticular
perforation, a postoperative infection, complicated
diverticulitis, malignancy or immunosuppression,
delayed surgery and, logically, ICU admission, but the
study did not analyze the impact of adequate antibiotic.
All these factors should be considered in the future
when analyzing an appropriate antibiotic therapy.
Moreover, the appropriateness of an antibiotic therapy
might also depend on the causative agents and the type of
intrabdominal foci. A retrospective study revealed that the
mortality of patients with P. aeruginosa of an intraabdominal
non-hepatobiliary source who received inappropriate antibio-
tic therapy as higher than that of adequately treated patients.59
However, discordant antimicrobial therapy has no impact on
the mortality of patients with hepatobiliary disease.
As in UTIs, the identifications of risk factors for
ESBL-IAIs might be useful for selection of the initial
antibiotic therapy. In recent studies in patients with bacter-
emia from an intrabdominal source, carbapenem therapy
was associated with a lower mortality rate than that of
piperacillin-tazobactam treatment.13
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The influence of adequate antibiotic therapy on the
incidence of postoperative surgical site infections has
not been adequately studied. In a recent worldwide
study of 567 patients with acute cholecystitis treated
mainly with surgery, factors associated with the pre-
sence of MDR microorganisms (mainly ESBL-
producing enterobacteria) were the presence of a health-
care infection and recent antibiotic therapy. However,
factors associated with a poor outcome were the pre-
sence of diffuse peritonitis and an inadequate source
control, but the inadequacy of the empiric antibiotic
therapy had no influence on mortality.60
In conclusion, in cUTIs, due to its low rates of mortal-
ity, an appropriate antibiotic therapy seems to have little
impact on the outcome mortality but has an impact on the
clinical outcome, hospital stay and risk of relapse. In
severe cIAIs, inadequate antibiotic therapy has an impact
on the outcome, with the control of the infection source
being essential. The impact of adequate empiric antibiotic
therapy on less severe IAIs when treated early with sur-
gery (cholecystectomy, appendicectomy) is less relevant.
Ceftolozane/tazobactam in the
treatment of complicated
intra-abdominal infections
Clinical trials
A phase II prospective, double-blind, randomized and
multicenter trial compared C/T plus metronidazole to
meropenem for the treatment of cIAIs.33 Hospitalized
adult patients with cIAIs that required surgical interven-
tion were randomized 2:1 to receive C/T (1.5 g IV q8h)
plus metronidazole (500 mg IV q8h) or meropenem (1
g IV q8h). Clinical response at the test-of-cure visit in
the microbiologically modified intent-to-treat (mMITT)
and microbiologically evaluable (ME) per-protocol
populations was the primary endpoint. Eighty-two
patients received C/T, and 39 patients received merope-
nem. Clinical cure was observed in 83.6% (51/61) of
patients who received C/T versus 96% (24/25) of
patients in the meropenem arm (difference −12.4%;
95% CI,−34.9–11.1%) in the mMITT population, and
in 88.7% (47/53) and 95.8% (23/24) of the patients
who received C/T and meropenem, respectively (differ-
ence −7.1%; 95% CI, −30.7% to 16.9%), in the ME
population.33
The ASPECT-cIAIs (assessment of the safety profile
and efficacy of C/T in complicated intra-abdominal
infections) combined two identical prospective, double-
blind, randomized, multicenter phase III clinical trials
that compared C/T plus metronidazole with meropenem
for the treatment of cIAIs. Hospitalized adult patients
with cIAIs that required surgical intervention were ran-
domized 1:1 to receive C/T (1.5 g IV q8h) plus metro-
nidazole (500 mg IV q8h) or meropenem (1 g IV q8h)
for 4–14 days. The C/T dose for patients with ClCr of
30–50 mL/minute was reduced to 750 mg every 8 h, and
the meropenem dose was reduced to 1 g every 12 h. The
study endpoints were to demonstrate statistical noninfer-
iority in clinical cure rates in the mMITT and ME
populations using a noninferiority margin of 10% at
the test-of-cure (TOC) visit (24–32 days from the start
of therapy). Of 993 patients that were randomized only
806 (81.2%) met the criteria for the mMITT population.
Statistical noninferiority was demonstrated in both
populations. The clinical cure rates were 83% (323/
389) for C/T plus metronidazole and 87.3% (364/417)
for meropenem in the mMITT population (weighted
difference, −4.2%; 95% CI, −8.91–0.54), and 94.2%
(259/275) for C/T plus metronidazole and 94.7% (304/
321) for meropenem (weighted difference, −1.0; 95%
CI, −4.52–2.59) in the ME population.
Most diagnoses were appendicular perforation or
peri-appendicular abscess (43.3%) and peritonitis was
present in >80% of both patient populations. The dis-
tribution of pathogens and the per-pathogen clinical cure
rates were similar in both arms, and most infections in
both populations were polymicrobial. Resistant bacteria
were slightly represented but equally distributed: 29
ESBL-producing Enterobacteriaceae in each group
(overall rate of 7.2%), and three of the 52 isolated
P. aeruginosa were resistant to three or more classes
of antipseudomonal antibiotics. In patients with ESBL-
producing Enterobacteriaceae, the clinical cure rate was
95.8% (23/24) for C/T plus metronidazole and 88.5%
(23/26) for meropenem, and clinical cure rates of 100%
(13/13) and 72.7% (8/11) were obtained in patients with
CTX-M-14/15 ESBLs, respectively. The type and fre-
quency of adverse events (AEs) was similar in both
groups (44.0% versus 42.7%).
Real-life clinical experience
As mentioned above, C/T has proven effective for the treat-
ment of cIAIs, with a clinical success rate of more than 80%
in RCTs,33,34 but MDR microorganisms were not very well
represented, particularly MDR P. aeruginosa,for which
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ceftolozane–tazobactam might be important. Therefore, sev-
eral case reports and series have focused on analyzing the
outcome of patients with cIAIs due to MDR P. aeruginosa
who were treated with C/T in daily practice.
Table 3 shows the clinical characteristics and outcomes of
different cases of cIAIs due to MDR P. aeruginosa (the last
five cases are due to XRD P. aeruginosa) that were treated
with C/T.61–65 Overall, 10 of 13 (76.9%) exhibited a good
clinical outcome, and the other three died; in addition, in two
(15.4%) of the cases with favorable clinical outcome showed
colonization with a C/T-resistant P. aeruginosa isolate. Each
of two other unicenter observational studies of MDR
P. aeruginosa infections treated with C/T (one with 38
patients and the other with 58 patients) also included four
cases of cIAIs, and in both studies three (75%) of the cIAI
patients exhibited a good clinical outcome.41,44
Two published multicenter retrospective studies also
included some cases of cIAIs treated with C/T. In one study,
which was performed in Italy,66 C/T was administered to 101
patients with diverse infections, including 13 (12.8%) with
cIAIs. Almost half of the P. aeruginosa strains included in
this series were XDR (51%), concomitant antibiotics were
administered to 35% of patients, and high doses of C/T (3
g every 8 h) were given to 30.7% of patients, including two
patients with cIAIs. The overall clinical success rate for cIAIs
was 76.9% (10 of 13). The other multicenter study, which was
performed in the USA,67 included 205 patients, and 20 (9.8%)
of these patients had a cIAI. Thirty-day or inpatient mortality
was observed in two (10%) of the patients with cIAI, clinical
success was seen in 15 (75%) of the cIAI patients, and
a microbiological cure was achieved in 18 (90%).
The reasons for clinical failure in patients treated with C/
T for P. aeruginosa infections have been analyzed. The risk
factors associated with clinical failure that have been identi-
fied are a higher Simplified Acute Physiology Score-II
(SAPS-II) score,62 sepsis,66 the administration of continuous
renal replacement therapy during C/T treatment,66 and an
inadequate source control.41 In a unicenter study,
a comparative univariate analysis evaluating risk factors for
clinical failure found significant differences in disease sever-
ity, ventilator-dependent respiratory failure, XDR profile,
high-risk clone ST175, negative control culture, and resis-
tance development, but the multivariate analysis only identi-
fied ventilator-dependent respiratory failure as an
independent risk factor.44 One study also found that the
initiation of C/T treatment within 4 days of culture collection
is a significant predictor of survival, clinical success, and
microbiological success.67 Concomitant anti-pseudomonalT
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therapy or high doses of C/T have not been identified as
significant risk factors.
Another issue of concern is the selection of
C/T-resistant strains due to mutations or overexpression
in the resident AmpC β-lactamase during therapy,44 which
has been observed in some cases of intraabdominal
infections,41,61,62 particularly in those with inadequate
source control.41
Ceftolozane/tazobactam in the
treatment of complicated urinary
tract infections
Clinical trials
The evidence for the efficacy of C/T in cUTIs is based on
the ASPECT-cUTI phase III trial, which was a prospective
randomized, double-blind, double-dummy-controlled non-
inferiority trial undertaken in 135 centers worldwide.68
This trial included 1,083 hospitalized patients with clinical
evidence of APN (82%) or complicated lower UTI (18%),
defined by symptoms of acute cystitis plus one of the
following: obstructive uropathy, indwelling urinary cathe-
ter or anatomical urogenital tract abnormality. Patients
with severe progressive disease or septic shock, immuno-
suppressed patients, patients with severe renal failure (ClCr
<30 ml/min), patients with an infection that the investiga-
tor determined would require more than 7 days of therapy
and patients who were not expected to survive 5 weeks
were excluded. Only 7.8% of the patients had bacteremia.
The infection was monomicrobial in 97% of the infections,
E. coli was isolated in 79% of the cases, 14.8% of the
patients had ESBL-producing Enterobacteriaceae, and
only 2.9% of the infections were due to P. aeruginosa.
The participants were randomized 1:1 to receive C/T at 1.5
g/8 h (n=543) or levofloxacin at 750 mg (n=540) daily for
7 days. Of note, approximately 25% of the isolated patho-
gens were resistant to quinolones, and 2.7% to C/T.
Based on the composite cure outcome, which included
clinical cure and microbiological eradication at 5–9 days
after the last dose, C/T was superior to levofloxacin in both
the mMITT analysis (77% versus 68%) and the per-protocol
analysis (83% versus 75%). However, if only the patients
with susceptible pathogens were analyzed, the outcomes
were similar. As expected for ESBL-producing E. coli
infections, higher microbiological cure rates were obtained
with C/T [27/36 (75%) versus 18/36 (50%)] due to the high
resistance rates to fluoroquinolones. For P. aeruginosa
infections, the microbiological eradication rates obtained
with C/T and levofloxacin were 86% (6/7) and 58%
(7/12), respectively. Based on these data, the clinical and
microbiological efficacy of C/T in MDR pathogens, which
is one of the main indications for this drug, is insufficient
because the efficacy of C/T for ESBL infections has not
been compared with the gold-standard antibiotic therapy,
carbapenems, and patients with XDR P. aeruginosa infec-
tions were not included. In addition, only a few patients had
severe infections, because bacteremia was uncommon.69
Real-life clinical experience
Most of the real-life published clinical experience on C/T
involves the treatment of MDR P. aeruginosa cUTIs. The
published studies are case reports and small series of dif-
ferent types of MDR or XDR P. aeruginosa that include
cases of cUTIs.41,62 Among these studies, the overall clin-
ical efficacy was approximately 70%, and 30–50% of the
cases were treated with high doses of C/T. In our limited
experience with patients with P. aeruginosa, patients with
cUTI are usually treated with low C/T doses (only one case
with a prostatic abscess received high C/T doses).41
In a study that included 58 patients (cUTI was
the second type of treated infection), 8 of 10 patients
with cUTI were cured.44 In another study that included
23 patients, among which seven had a cUTI (all were
treated with conventional C/T doses), only one showed
clinical failure.65 Furthermore, in four studies that
included a limited number of cases of cUTIs, none of the
five included cases treated with low doses of C/T showed
clinical failure.61–64 A recent nationwide multicenter
Italian study66 with 101 patients treated with C/T for
serious P. aeruginosa infections showed clinical failure
in only one of 14 (7.1%) patients with a cUTI. Overall,
30% of the cases were treated with high doses, but the
dose to patients with a UTI was not specified. In the
largest series, which included 205 patients with MDR
Pseudomonas infection treated with C/T, the overall clin-
ical and microbiological cure rates were 73.7% and 70.7%,
respectively, and those for patients with cUTIs were 89%
(22/25) (89%) and 89% (22/25), respectively.67
In summary, 49/57 (86%) of the cases with MDR
P. aeruginosa cUTIs treated with C/T, usually with conven-
tional doses (when specified), were cured, and this percen-
tage is higher than the overall cure rate. In these studies
patients with severe infections were included, because
a significant percentage had bacteremia, and some patients
had undergone solid organ or hematopoietic stem cell trans-
plantation, had EERD and/or were admitted to the ICU.
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Safety and tolerability of
ceftolozane/tazobactam
C/T has a safety and tolerability profile similar to that of
any other cephalosporin, as demonstrated by RCTs, which
showed a percentage of AEs ranging from 35% to 50%
[overall 438 AEs over 1,097 (39.9%) patients treated with
C/T] and no significant differences with respect to their
comparators. Between 3% and 17% of the patients pre-
sented severe adverse events (SAEs), although only three
cases of Clostridium difficile infection were considered to
be related to C/T. In the RCTs, no drug-related death was
reported, and the most frequently reported AEs (with an
incidence greater than 5% in either indication) experienced
by the patients treated with C/T were nausea, headache,
diarrhea, and pyrexia.33,34,68
In a postmarketing safety evaluation, seven cases of med-
ication errors were reported to the FDA: these patients were
administered a dose of C/T that was 50% higher than the
prescribed dose and experienced no AEs related to the med-
ication error.70 Similarly, a multicenter, retrospective study of
patients with carbapenem-resistant P. aeruginosa infections
who were treated with C/T ranging from 375 mg to 3,000 mg
every 8 h for 5–27 days observed only two AEs (self-limited
diarrhea and peripheral eosinophilia with eosinophiluria pos-
sibly due to interstitial nephritis), which resolved after the
drug was stopped.63 In a retrospective series of 38 patients
with XDR P. aeruginosa infections treated with C/T for 15.5
days (range of 3–62 days), 60.5% of the patients were admi-
nistered doses of 3 g every 8 h, and no AEs that forced the
withdrawal of the antibiotic were observed.41
In summary, C/T is a cephalosporin with a safety profile
and tolerability similar to those of the remaining cephalospor-
ins and can be administered to patients with cIAIs or cUTIs,
and in particular, C/T can be used, if necessary, at doses of up
to 3 g every 8 h for a prolonged time (at least for 4 weeks).
Conclusions and place in therapy
C/T is a cephalosporin with activity against most ESBL-
producing Gram-negative rods and against MDR or XDR
P. aeruginosa. Different published RCTs have reported the
efficacy and safety profile for the treatment of cIAIs and
cUTIs, and the results show that the drug has a favorable PK/
PD profile. The use of C/T for the treatment of these infections
should be considered in two clinical situations: as a potential
alternative therapy to carbapenems in a carbapenem-sparing
strategy, or for the treatment of infections caused by MDR or
XDR P. aeruginosa.
In the first clinical situation, the use of C/T for the
treatment of ESBL-producing Gram-negative rod infections
has been proposed for the recovery of carbapenem activity
in a given health institution. It has been well demonstrated
that the overuse of carbapenems can condition the appear-
ance and dissemination of carbapenem-producing
Enterobacteriaceae (CPE), which would significantly limit
the potential use of these drugs. The reduction in the use of
carbapenems is associated with a decrease in the frequency
of CPE infections. In centers where ESBL-producing
Gram-negative rod infections are endemic, a carbapenem-
sparing strategy (in either first-line therapy or de-escalation
therapy) could be effective in preventing the appearance
and dissemination of CPE. The recently published results
of the MERINO study13 demonstrate the superiority of
a carbapenem regimen over piperacillin–tazobactam for
the treatment of infections caused by ceftriaxone-resistant
E. coli or K. pneumoniae, and thus this therapeutic alter-
native should not be used in a carbapenem-sparing strategy.
However, the results of the MERINO study could have been
subject to numerous biases, both in the selection of patients,
in the choice of the primary outcome, in the inclusion of
patients from countries with different profiles and rates of
antimicrobial resistance, and in the manner of administra-
tion of piperacillin–tazobactam. Therefore, its conclusions
should be considered with caution.
Although there is no relevant clinical information, the
stability of C/T against AmpC beta-lactamases would
allow its alternative use to carbapenems for the treatment
of infections caused by SPACE organisms (Serratia,
Providencia, Acinetobacter, Citrobacter, Enterobacter).
C/T maintains its activity against P. aeruginosa spe-
cies with multiple resistance mechanisms (efflux pumps,
reduction uptake through porin channels, or modifica-
tion of penicillin-binding proteins). Several observa-
tional studies have found that C/T can be an effective
therapy for the treatment of serious infections caused by
MDR or XDR P. aeruginosa. In particular, when admi-
nistered at an adequate dose (usually up to 3 g every 8
h), C/T can act on the source of the infection and the
MIC value for C/T does not exceed 4 mg/L. C/T ther-
apy for these serious infections provides a clinical suc-
cess rate (in-hospital survival plus resolution of signs
and symptoms) of approximately 75%. Although the
published experience in the treatment of cIAIs or
cUTIs produced by MDR or XDR P. aeruginosa is
very limited, the absence of effective therapeutic alter-
natives with an acceptable safety profile would make C/
Escolà-Vergé et al Dovepress
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T a first-line therapeutic option for these infections.
Therefore, C/T should be routinely tested against every
Gram-negative rod, and particularly against MDR or
XDR P. aeruginosa.
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